Dancing, I agree. This is something that is overlooked by most investors. Icosapent ethyl is not an ideal target for generic companies. They can't go into mass production to flood the market with a cheeper product. I know most people don't share my perspective. I see Amarin as the company that has the advantage that a generic normally uses to capture the majority of the market.(my opinion) Sleven,
News 
Market Data 
Discover 
